In-Depth Analysis On Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Complete report available @ Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 26, 19, 3, 66, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Albireo Pharma Inc Allergan Plc Alnylam Pharmaceuticals Inc Amunix Operating Inc Aquinox Pharmaceuticals Inc Ardelyx Inc Arisaph Pharmaceuticals Inc ARMO Biosciences Inc AstraZeneca Plc Betagenon AB BioLineRx Ltd BiOrion Technologies BV Bird Rock Bio Inc BLR Bio LLC Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Can-Fite BioPharma Ltd Cardax Inc Carmot Therapeutics Inc Catabasis Pharmaceuticals Inc Cerenis Therapeutics Holding SA ChemoCentryx Inc CohBar Inc Conatus Pharmaceuticals Inc Connexios Life Sciences Pvt Ltd CymaBay Therapeutics Inc Daiichi Sankyo Company Ltd Dimerix Bioscience Pty Ltd Dong-A Socio Holdings Co Ltd DURECT Corp Dynavax Technologies Corp Eli Lilly and Company Enanta Pharmaceuticals Inc Exicure Inc FORMA Therapeutics Inc Galectin Therapeutics Inc Galmed Pharmaceuticals Ltd Gemphire Therapeutics Inc Genextra Spa Genfit SA GenKyoTex SA Gilead Sciences Inc GRI Bio Inc Hanmi Pharmaceuticals Co Ltd iCo Therapeutics Inc. Immuron Ltd Intercept Pharmaceuticals Inc Inventiva Ionis Pharmaceuticals Inc Jenrin Discovery Inc Kissei Pharmaceutical Co Ltd Kyorin Pharmaceutical Co Ltd Matinas BioPharma Holdings Inc MedImmune LLC Merck & Co Inc Mitochon Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp Naia Ltd NeuroVive Pharmaceutical AB NGM Biopharmaceuticals Inc Nippon Chemiphar Co Ltd Nitto Denko Corp Novartis AG NovaTarg Therapeutics Inc Novo Nordisk A/S Nuevolution AB Pfizer Inc Pharmaxis Ltd Promethera Biosciences SA ProMetic Life Sciences Inc Protalix BioTherapeutics Inc Regulus Therapeutics Inc Saje Pharma LLC Sancilio & Company Inc Shire Plc Stelic Institute & Co Inc TaiwanJ Pharmaceuticals Co Ltd Tiziana Life Sciences Plc TRACON Pharmaceuticals Inc Vascular Biogenics Ltd Verlyx Pharma Inc Viking Therapeutics Inc Virobay Inc Zydus Cadila Healthcare Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 07:36
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home